Invasive meningococcal disease (IMD) is responsible for serious morbidity and mortality with global estimates of 50,000-135,000 deaths annually. Due to the early non-specific symptoms of IMD, misdiagnosis is common and often results in late medical intervention. Despite the availability of antibiotic therapy, case fatality rate for IMD serogroups B and C among Australian children below 5 years of age is 5%; and 6-12% for adults over the age of 25. Moreover approximately 10-30% of people who survive IMD develop long-term consequences such as limb deformity, limb scarring, deafness and neurological deficits. In this program GPs can update their IMD awareness so that they are more familiar with which variants of IMD are prevalent, how to diagnose it, how to recommend vaccinations and make sure all at risk groups are covered with immunisations.
This interactive online learning activity is valued at 2 Hour(s) of continuing education.
Robina Town Centre Medical Centre, QLD
Professor Robert Booy
MBBS (Hons), MSc, MD, FRACP, FRCPCH
Head, Clinical Research
National Centre for Immunisation Research and Surveillance
Westmead Children’s Hospital
On completion of this program, haematologists will be better able to:
- Describe the pathogenesis of chronic lymphocytic leukaemia (CLL) and follicular lymphoma (FL), considering the implications of high risk markers and prognostic features
- Recall mechanisms of actions, indications, contra-indications, adverse effect profiles and Pharmaceutical Benefits Scheme listings of novel targeted therapies for relapsed and refractory CLL and follicular lymphoma
- Evaluate clinical trial evidence on efficacy and safety of novel targeted therapies
- Monitor and manage adverse events related to novel therapies and optimise health-related quality of life